Because a subset of patients with breast cancer and a pathogenic variant in BRCA1/2 will choose BCT, continuing to study and report their long-term outcomes is important for ensuring that adequate evidence is available to inform patients. The gene discussed is BRCA1; the disease is breast cancer.